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                              Circulating tumor cells are cells that have 
detached from the primary tumor or meta-
static tumor sites and entered the periph-
eral circulation. A limited number of 
markers are used for the isolation (ie, cell 
surface antigens) or detection (ie, various 
antigens or mRNAs) of circulating tumor 
cells. These markers include epithelial cell 
surface markers, such as the epithelial cell 
adhesion molecule (EpCAM; also known as 
CD326, ESA, HEA125, and TACSTD1); 
cytokeratins 7, 8, 18, 19, and 20; and more 
cancer-specific markers, such as HER2-
neu and mucin 1 for breast carcinoma 
(  1    –    3  ). Commercially available tests for iso-
lation and detection of circulating tumor 
cells include the CellSearch circulating 
tumor cell test (Veridex LLC, San Diego, 
CA) and other tests (  1    –    3  ). These tests use 
combinations of specific antibodies against 
these molecules and generally include anti-
bodies against EpCAM for cell isolation. 
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    Identification of specific subtypes of circulating tumor cells in peripheral blood of 
cancer patients can provide information about the biology of metastasis and 
improve patient management. However, to be effective, the method used to iden-
tify circulating tumor cells must detect all tumor cell types. We investigated whether 
the five subtypes of human breast cancer cells that have been defined by global 
gene expression profiling  —  normal-like, basal, HER2-positive, and luminal A and 
B  —  were identified by CellSearch, a US Food and Drug Administration  –  approved 
test that uses antibodies against the cell surface  –  expressed epithelial cell adhesion 
molecule (EpCAM) to isolate circulating tumor cells. We used global gene expres-
sion profiling to determine the subtypes of a well-defined panel of 34 human breast 
cancer cell lines (15 luminal, nine normal-like, five basal-like, and five Her2-positive). 
We mixed 50-150 cells from 10 of these cell lines with 7.5 mL of blood from a single 
healthy human donor, and the mixtures were subjected to the CellSearch test to 
isolate the breast cancer cells. We found that the CellSearch isolation method, 
which uses EpCAM on the surface of circulating tumor cells for cell isolation, did 
not recognize, in particular, normal-like breast cancer cells, which in general have 
aggressive features. New tests that include antibodies that specifically recognize 
normal-like breast tumor cells but not cells of hematopoietic origin are needed. 
    J Natl Cancer Inst 2009;101:  61    –    66     
However, it is unclear whether such tests 
can detect all tumor subtypes. We investi-
gated whether the CellSearch test could 
recognize all subtypes of breast cancer, 
including normal-like, basal, HER2-
positive, and luminal A and B tumor cells. 
  The CellSearch circulating tumor cell 
test is the only diagnostic test that is cur-
rently approved by the US Food and Drug 
Administration as an automated test to 
detect and enumerate circulating tumor 
cells (  4  ). Brieﬂ  y, a blood sample that con-
tains many leukocytes and few circulating 
tumor cells is drawn into 10-mL CellSave 
Preservative Tubes (Veridex LCC), which 
contain EDTA as an anticoagulant and a 
cellular preservative. The blood is main-
tained at room temperature and subse-
quently processed within 72 hours of 
collection by use of the CellSearch system 
(Veridex LLC), which consists of the 
CellTracks Autoprep (an automated sample 
preparation system), the CellSearch epithe-
lial cell kit (to enrich for cells expressing 
EpCAM and to label nuclei, leukocytes, 
and epithelial cells), and the CellSpotter 
Analyzer (a semiautomated ﬂ  uorescence-
based microscopy system that permits 
computer-generated reconstruction of cel-
lular images). By use of the CellSearch 
epithelial cell kit, circulating tumor cells 
are isolated with anti-EpCAM antibodies 
coupled to microscopic iron particles, and 
complexes of circulating tumor cells bound 
to anti-EpCAM  –  coupled iron particles are 
“pulled” out of the blood sample by use of 
powerful magnets. Unbound cells and the 
remaining plasma are aspirated, and the 
immunomagnetically isolated cells are per-
meabilized and stained with 4 ′  ,6-diamidino-
2-phenylindole (to detect nuclei); 
anti-CD45 antibodies labeled with allophy-
cocyan (to detect leukocytes); and anti-
cytokeratin 8, 18, and 19 antibodies labeled 
with phycoerythrin (to detect epithelial 
cells). After incubation with staining 
reagents, the magnetic separation is 
repeated and excess staining reagents are 
removed by aspiration. In the ﬁ  nal process-
ing step, the immunomagnetically isolated 
cells are resuspended in a MagNest Cell 
Presentation Device (Veridex LLC). This 
device consists of a chamber and two mag-
nets that orient the immunomagnetically 
labeled cells for analysis by use of the 62   Brief Communication | JNCI  Vol. 101, Issue 1  |  January 7, 2009
CellSpotter Analyzer, a four-color semiau-
tomated ﬂ  uorescence microscope. Finally, 
circulating tumor cells that are deﬁ  ned as 
nucleated cells with a round to oval mor-
phology that are positive for anti-
cytokeratin antibody binding and negative 
for anti-CD45 antibody binding (  5  ) are 
identiﬁ  ed by an operator. 
  Results of the CellSearch test have been 
used to monitor disease progression and 
therapy efﬁ  cacy in metastatic prostate (  6  ), 
colorectal (  7  ), and breast (  8  ) cancer. For 
patients with advanced breast cancer, the 
number of circulating tumor cells as deter-
mined by the CellSearch test has been 
shown to have prognostic value (  8    –    14  ). In 
addition, a change from the baseline num-
ber of circulating tumor cells after the ﬁ  rst 
cycle of therapy appears to distinguish 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  Identification of specific subtypes of circu-
lating tumor cells in the peripheral blood of 
cancer patients can provide important prog-
nostic information, but to be effective, the 
method used must recognize all tumor cell 
types.         
    Study design 
  The subtype of 19 well-characterized breast 
cancer cell lines was obtained by use of 
gene expression profiling, including normal-
like, basal-like, HER2-positive, and luminal 
A and B. Cells from each line were mixed 
with blood from a healthy donor and sub-
jected to the CellSearch circulating tumor 
cell assay.   
    Contribution 
  The CellSearch assay, which uses epithelial 
cell adhesion molecules on the cell surface, 
did not recognize normal-like breast can  -
cer  cells, although other subtypes were 
recognized.   
    Implications 
  Normal-like breast cancer cells have espe-
cially aggressive features, and so assays 
that recognize this subtype would provide 
valuable prognostic information. New 
assays are needed that include antibodies 
that specifically recognize this breast can-
cer subtype but not other cell types, includ-
ing those of hematopoietic origin.   
    Limitations 
  Only homogeneous breast cancer cell lines 
with known subtypes were investigated. 
    From the Editors       
    
patients who have responded to systemic 
therapy (who have a decreased number of 
circulating tumor cells) from those who 
have not (who have an increased number of 
circulating tumor cells) (  15  ). 
  Five subtypes of human breast cancers 
have been identiﬁ  ed by global gene expres-
sion proﬁ  ling, including normal-like, basal, 
HER2-positive, and luminal A and B (  16  ). 
The normal-like and basal subtypes, which 
represented 7.8% and 25% of all breast 
cancers, respectively, in a cohort of 344 
breast tumor samples from patients with 
lymph node  –  negative disease (  17  ), are in 
general negative for estrogen receptor 
(  ESR1  ), progesterone receptor, and HER2-
neu, and so lack the molecular targets for 
endocrine therapy and anti-HER2 –  directed 
therapy and therefore have worse treat-
ment options than other subtypes. Because 
each breast cancer subtype has distinct 
prognostic and therapeutic characteristics 
(  16  ,  18  ), it is important to establish whether 
each breast cancer subtype expresses the 
cell surface antigens that are used in assays 
to isolate and detect circulating tumor 
cells. It is also important to identify which 
breast cancer subtypes do not express an 
antigen and to determine which antibodies 
could be used instead of or in addition to 
antibodies that are included in the test for 
circulating tumor cells. 
  To investigate whether the CellSearch 
test recognized all ﬁ  ve breast cancer sub-
types that are characterized by their intrin-
sic gene expression proﬁ   les as previously 
described (  16  ,  18  ), we ﬁ  rst determined the 
subtypes of our well-deﬁ   ned panel of 34 
human breast cancer cell lines (  19  ) by 
global gene expression proﬁ  ling,  as 
described previously (  17  ). A previous analy-
sis of nearly 150 polymorphic microsatellite 
markers in this panel of 34 cell lines has 
shown that each of these 34 cell lines is 
unique and monoclonal (  20  ). As determined 
by the expression of genes in the intrinsic 
gene set (  16  ,  17  ), the complete panel con-
tained 15 luminal cell lines (ie, no clear-cut 
discrimination between luminal A and B), 
nine normal-like lines, ﬁ  ve basal-like lines, 
and ﬁ  ve HER2-positive cell lines (  Table 1  ). 
To validate the gene expression proﬁ  ling 
data, transcript levels of 14 candidate genes 
were remeasured with Affymetrix GeneChip 
Exon 1.0 ST Arrays (Affymetrix UK Ltd., 
Wickham la Wooburn Grn, UK) and 
real-time reverse transcriptase  –  polymerase 
chain reaction. The 14 candidate genes 
that may as such enable dis    crimination 
between the breast cancer subgroups 
included genes that are more speciﬁ  c for 
cells of hematopoietic origin (  CD44   and 
  CD45  ); epithelial cell  –  speciﬁ   c genes such 
as those encoding cytokeratins, EpCAM, 
and mucin 1; genes encoding markers 
speciﬁ   c for the breast cancer subgroups 
(  ESR1  ,   ERBB1  ,   ERBB2  ,   CAV1  , and   CD24  ); 
and genes for two well-known epithelial  – 
mesenchymal transition markers (  TWIST1   
and   VIM  ). Transcript levels of these 14 
genes in all the 34 cell lines were compared 
with those measured in whole-blood cells 
from 23 different blood donors before (n = 
6 samples) and after (n = 23 samples) being 
subjected to EpCAM-based CellSearch 
enrichment to establish which genes were 
not expressed by blood cells and could be 
used to speciﬁ   cally identify the epithelial 
tumor cells (  Table 1  ). The study was 
approved by the Erasmus MC Institutional 
Review Board. Blood samples were col-
lected from healthy volunteers after written 
informed consent was obtained.   Supple-
mentary Table 1   (available online) lists the 
gene expression assays used.         
  We next randomly selected 19 of the 34 
cell lines; incubated each cell line with 
ﬂ  uorochrome-conjugated antibodies against 
CD45, CD24, CD44, or EpCAM, which 
were chosen to enable a distinction between 
CD45-positive cells of hematopoietic ori-
gin, CD45-negative and EpCAM-positive 
breast cancer cells, and CD45-negative, 
CD24-negative, and CD44-positive breast 
cancer stem cells (  21  );       and used ﬂ  ow cytom-
etry to measure the expression of each 
marker by each cell line (  Table 2  ). Next, an 
aliquot (50  –  150 cells per aliquot) of each of 
these 19 cell lines was added to a separate 
7.5-mL sample of peripheral blood from a 
single healthy volunteer donor, and the 
mixtures were subjected to the EpCAM-
based CellSearch assay to isolate circulat  -
ing tumor cells. Gene expression data of 
the isolated cells showed that cells with a 
luminal or HER2-positive subtype were 
generally isolated by the assay, whereas 
cells with a normal-like subtype, which lack 
EpCAM expression, were not isolated or 
were only partially isolated (eg, MDA-MB-
231 cells, which have marginal EpCAM 
expression) (  Figure 1  ;   Supplementary 
Table 2  , available online). We found that 
the cell lines with the normal-like subtype jnci.oxfordjournals.org    JNCI | Brief Communication 63
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expressed high mRNA levels of the epithe-
lial  –  mesenchymal transition markers, 
TWIST1 (  TWIST1  ) and vimentin (  VIM  ) 
(one-way analysis of variance, two-sided 
  P   = .03 and   P   < .001, respectively) (  Table 1  ); 
however, MDA-MB-231 cells expressed 
vimentin but did not appear to express 
TWIST1 (  Supplementary Table 3  , avail-
able online).                 
  Cells with a normal-like breast cancer 
subtype express high levels of genes that 
are characteristic of basal epithelial and 
adipose cells and low levels of genes that 
are characteristic of luminal epithelial cells 
(  16  ). The normal-like breast cancer subtype 
is the only subtype that displays the puta-
tive tumor-initiating stem cell phenotype, 
which includes low expression of CD24 
and high expression of CD44 (  21  ,  22  ) 
(  Table 2  ) and has high expression of 
both vimentin and TWIST1 (  Table 1  ). 
Expression of vimentin and TWIST1 has 
been used to identify cells that have under-
gone the epithelial  –  mesenchymal transi-
tion, a process that has been linked to the 
generation of cells with properties of stem 
cells and to the ability of breast cancer cells 
  Table 2    .       Immunological assessment of antigens in breast cancer cell lines with different intrinsic subtype characteristics and circulating 
tumor cell recovery  *     
    Intrinsic subtype No. of cell lines
Flow cytometry,    †     MFI CellSearch,    ‡     % of cells 
recovered (95% CI)    CD45 CD24 CD44 EpCAM   
    Normal-like 6 <5 <5 >1000 <5 2 (0 to 6)  §   
  Basal-like 5 <5 5  –  20 200  –  1000 20  –  200 48 (36 to 61) 
  Luminal 5 <5 5  –  20 5  –  20 20  –  200 75 (62 to 89) 
  HER2-positive 3 <5 5  –  20 <5 20  –  200 85 (61 to 108)   
    *     MFI = mean fluorescence intensity; EpCAM = epithelial cell adhesion molecule; CI = confidence interval; 7AAD = 7-amino-actinomycin D; FITC = fluorescein 
isothiocyanate.   
      †       Cultured human breast cancer cell lines were incubated with the following fluorochrome-conjugated monoclonal antibodies: EpCAM conjugated with FITC 
(clone EBA-1; BD Biosciences, San Jose, CA), CD24 conjugated with FITC (clone SN3; eBioscience, Inc., San Diego, CA), CD44 conjugated with R-phycoerythrin 
coupled to the cyanine dye Cy7 (PE-Cy7, clone HIB19; eBioscience), and CD45 conjugated with allophycocyanin (clone 2D1; BD Biosciences). We used 7AAD 
(Sigma-Aldrich, St Louis, MO; 1   µ  g/mL) to control for viability. Cells were then analyzed on a Canto flow cytometer (BD Biosciences). To exclude nonviable 
cells from analysis, only 7AAD-negative (viable) cells were evaluated for antigen expression. Unstained cells were used as a negative control. Only cells that 
expressed EpCAM were captured by the anti-EpCAM antibody present in the CellSearch circulating tumor cell profile kit. In addition, as shown in   Figure 1   and 
  Supplementary Table 2   (available online), MDA-MB-231 cells with marginal EpCAM expression were only partially (10 of 82 added tumor cells, or approximately 
12%) captured by the CellSearch antibody, indicating that anti-EpCAM antibodies from the EBA-1 clone (BD Biosciences) and from the CellSearch circulating 
tumor cell kit have similar sensitivities and specificities.   
      ‡       Data are the average (95% CI) of one representative experiment performed in duplicate for the given number of cell lines. Blood samples containing EDTA 
(7.5-mL aliquots of blood) from a single healthy blood donor were obtained from CellSave Preservative Tubes (Veridex LCC, San Diego, CA). To each sample, 
20   µ  L of a cell suspension containing 50  –  150 cultured cells from the indicated subtype of human breast cancer was added. To determine the actual viable cell 
number, a 100-  µ  L aliquot of the cultured cells was incubated with 10   µ  L of 7AAD (1   µ  g/mL) and 100   µ  L of fluorescent beads (Beckman  –  Coulter, Inc., Miami, FL). 
After a 15-minute incubation at room temperature, 2 mL of phosphate-buffered saline was added, and samples were analyzed on a Calibur flow cytometer 
(BD Biosciences). At least 10    000 beads were acquired to estimate the number of 7AAD-negative (viable) cells. The efficiency of retrieving the tumor cells was 
controlled by counting the exact number of viable cells that were drawn in triplicate by flow cytometry and by light microscopy after serial dilution. To establish 
the number of circulating tumor cells recovered, samples were processed on the CellTrack AutoPrep analyzer (Veridex LLC) with the CellSearch circulating tumor 
cell profile kit (Veridex LLC), which uses microscopic iron particles coupled to anti-EpCAM to enrich for circulating tumor cells. The number of circulating tumor 
cells (ie, cells stained with the nuclear dye, 4  ′  ,6-diamidino-2-phenylindole, that are positive for cytokeratin 8, 18, and 19, and negative for CD45) were determined 
on the CellSpotter analyzer (Veridex LLC), according to the manufacturer’s instructions (for full flow cytometry and CellSearch recovery data on these 19 
cell lines, see   Supplementary Table 2  , available online).   
    §     One-way analysis of variance was used to test for differences between the four subgroups present in the cell lines, with   P   < .05 from a post hoc Dunett t test 
being considered statistically significant. All statistical tests were two-sided.     
to enter the circulation and seed metastases 
(  23    –    25  ). Thus, the normal-like breast can-
cer cell subtype is an important target for 
the development of individualized therapy 
and should not be overlooked when assess-
ing circulating tumor cells. Intrinsic breast 
cancer subtypes are easily missed in analy-
ses that use only crude, standard clinical or 
pathological criteria such as hormone 
receptor and HER2 status. Therefore, our 
results, which are based on a distinction in 
breast cancer subtypes determined by 
global gene expression proﬁ  ling, cannot be 
compared with those of Cristofanilli et al. 
(  8  ), who did not ﬁ   nd differences in the 
number of circulating tumor cells between 
breast cancer cell subtypes that were deﬁ  ned 
only by hormone receptor and HER2 
status. 
  New tests that include antibodies that 
speciﬁ   cally recognize normal-like breast 
tumor cells but not cells of hematopoietic 
origin are needed. As shown in   Table 1  , the 
phenotype of circulating leukocytes in the 
healthy blood donors before and after 
EpCAM-based CellSearch enrichment was 
characterized by the high expression of 
vimentin and CD44 mRNA and the low 
expression of CD24 mRNAs. Because anti-
bodies against vimentin and CD44 also 
bind to cells of hematopoietic origin, these 
antibodies would not be suitable for the 
detection of circulating tumor cells that 
have an epithelial  –  mesenchymal transition 
origin or putative breast cancer stem cells. 
However, current strategies for detecting 
circulating tumor cells can be improved to 
allow assessment of these normal-like cells 
by selecting antigens that are ubiquitously 
and abundantly present and that can be 
made accessible for isolation with immuno-
beads on normal-like cells but that are 
absent on cells of hematopoietic origin. 
When selecting antigens to use for isolat-
ing circulating normal-like breast cancer 
cells, it must be emphasized that clinical 
(breast) cancer samples consist of heteroge-
neous cell populations and always contain 
leukocytes and other types of blood cells; 
we circumvented this problem by using 
homogeneous cell lines. Examples of mem-
brane antigens that might fulﬁ  ll the criteria 
of being ubiquitously and abundantly pres-
ent on normal-like cells but absent on cells jnci.oxfordjournals.org    JNCI | Brief Communication 65
of hematopoietic origin are mucin 1 and 
caveolin 1. Gene transcripts of caveolin 1, 
an approximately 22-kDa integral mem-
brane protein, and mucin 1, a 350-kDa 
glycoprotein that protects the cell surface, 
were ubiquitously expressed in all normal-
like human breast tumor cell lines, with the 
apparent expression of caveolin 1 being 
higher (gene transcript expression range = 
1.42  –  13.42, relative to the expression of 
  HMBS  ,   HPRT1  , and   GUSB  ) than that of 
mucin 1 (gene transcript expression range = 
0.06  –  0.56, relative to the expression of 
  HMBS  ,   HPRT1  , and   GUSB  ) (  Table 1  ; 
  Supplementary Table 3  , available online). 
Furthermore, in our 344 clinical breast 
cancer samples (  17  ), decreased expression 
of EpCAM was associated with increasing 
   
    Figure 1    .       Immunological assessment of antigens in breast cancer cell 
lines representing the four intrinsic breast cancer subtypes. Data from 
two normal-like breast cancer cell lines, one basal-like cell line, one 
luminal cell line, and one HER2 (ERBB2)-positive cell line are shown. 
Cell surface antigens on tumor cells were assessed individually by incu-
bating 10 
6   cultured human breast cancer cells with the following 
ﬂ   uorochrome-conjugated monoclonal antibodies: anti-EpCAM conju-
gated with FITC (clone EBA-1; BD Biosciences, San Jose, CA), anti-CD24 
conjugated with FITC (clone SN3; eBioscience, Inc., San Diego, CA), or 
anti-CD44 conjugated with R-phycoerythrin coupled to the cyanine dye 
Cy7 (PE-Cy7, clone HIB19; eBioscience). We used 7AAD (Sigma-Aldrich, 
St Louis, MO) to assess viability. Only viable (7AAD negative) cells 
were analyzed for antigen expression (  red histograms  ). Unstained cells 
(  black histograms  ) were used as a negative control. Data are from one 
representative experiment that was performed three times. Results 
were similar for all three experiments. EpCAM = epithelial cell adhe-
sion molecule; FITC = ﬂ   uorescein isothiocyanate; 7AAD = 7-amino- 
actinomycin D.       
expression of caveolin 1 (Spearman  r    s   =    0.26, 
  P   < .001). Consequently, antibodies against 
antigens such as caveolin 1 might be able to 
speciﬁ   cally detect circulating tumor cells 
from normal-like breast tumors. 
  A limitation of this study is our use of 
homogeneous breast cancer cell lines of 
known subtypes instead of blood samples 
from patients with breast cancer that had 
been subtyped. Detection of normal-like 
breast cancer cells in clinical (breast) cancer 
samples, which consist of heterogeneous 
cell populations, will require an assay that 
uses a mixture of antibodies against differ-
ent cell surface antigens that are present on 
circulating tumor cells but absent on cells 
of hematopoietic origin. Such an assay 
should be thoroughly validated before 
clinical use, not only in cultured cell lines 
but also in clinical samples of known in  -
trinsic breast cancer subtype, as described 
previously for assays relying only on anti-
EpCAM antibodies (  5  ). 
  In conclusion, an EpCAM-dependent 
assay could not detect normal-like breast 
tumor cells. In the future, the identiﬁ  cation 
of antibodies that speciﬁ  cally detect nor-
mal-like breast cancer cells (which in gen-
eral have aggressive features) and their 
inclusion in the CellSearch assay may 
improve the sensitivity and feasibility of 
that assay without a loss of speciﬁ  city.       
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